Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Tri Locum Partners LP

Tri Locum Partners LP decreased its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 150,788 shares of the company’s stock after selling 641 shares during the quarter. Inspire Medical Systems makes up 5.8% of Tri Locum Partners LP’s portfolio, making the stock its 5th biggest position. Tri Locum Partners LP owned 0.50% of Inspire Medical Systems worth $27,953,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Horizon Advisors Inc. increased its position in shares of Inspire Medical Systems by 885.7% in the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 124 shares during the last quarter. Huntington National Bank grew its stake in Inspire Medical Systems by 228.3% in the fourth quarter. Huntington National Bank now owns 174 shares of the company’s stock worth $32,000 after purchasing an additional 121 shares in the last quarter. Harbour Investments Inc. increased its holdings in Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after buying an additional 99 shares during the last quarter. AlphaQuest LLC raised its stake in Inspire Medical Systems by 7,275.0% during the fourth quarter. AlphaQuest LLC now owns 295 shares of the company’s stock valued at $55,000 after buying an additional 291 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Inspire Medical Systems by 61.9% during the 4th quarter. Quadrant Capital Group LLC now owns 327 shares of the company’s stock worth $61,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Robert W. Baird lowered their price target on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a report on Tuesday, February 11th. Truist Financial lowered their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Morgan Stanley reduced their price target on shares of Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. KeyCorp lowered their price objective on shares of Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Finally, Piper Sandler dropped their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $218.90.

Inspire Medical Systems Trading Up 0.5 %

NYSE INSP opened at $158.97 on Friday. The company has a 50-day moving average price of $162.86 and a two-hundred day moving average price of $181.25. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40. The stock has a market cap of $4.73 billion, a price-to-earnings ratio of 91.89, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. As a group, equities research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. This trade represents a 77.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. This trade represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.